Omega-3 Fatty Acid Supplementation During Pregnancy and Respiratory Symptoms in Children
Identifieur interne : 003666 ( Main/Exploration ); précédent : 003665; suivant : 003667Omega-3 Fatty Acid Supplementation During Pregnancy and Respiratory Symptoms in Children
Auteurs : María Consuelo Escamilla-Nu Ez ; Albino Barraza-Villarreal ; Leticia Hernández-Cadena ; Efraín Navarro-Olivos ; Peter D. Sly ; Isabelle RomieuSource :
- Chest [ 0012-3692 ] ; 2014.
Descripteurs français
- KwdFr :
- Acides gras omega-3 (administration et posologie), Adolescent, Adulte, Complications de la grossesse (), Compléments alimentaires, Femelle, France, Grossesse, Humains, Incidence, Issue de la grossesse, Jeune adulte, Mâle, Méthode en double aveugle, Naissance prématurée (), Nourrisson, Nouveau-né, Phénomènes physiologiques nutritionnels prénatals, Prise en charge prénatale (), Relation dose-effet des médicaments, Résultat thérapeutique, Syndrome de détresse respiratoire du nouveau-né (), Syndrome de détresse respiratoire du nouveau-né (épidémiologie), Âge gestationnel, Études de suivi.
- MESH :
- administration et posologie : Acides gras omega-3.
- épidémiologie : Syndrome de détresse respiratoire du nouveau-né.
- Adolescent, Adulte, Complications de la grossesse, Compléments alimentaires, Femelle, France, Grossesse, Humains, Incidence, Issue de la grossesse, Jeune adulte, Mâle, Méthode en double aveugle, Naissance prématurée, Nourrisson, Nouveau-né, Phénomènes physiologiques nutritionnels prénatals, Prise en charge prénatale, Relation dose-effet des médicaments, Résultat thérapeutique, Syndrome de détresse respiratoire du nouveau-né, Âge gestationnel, Études de suivi.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Adolescent, Adult, Dietary Supplements, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Acids, Omega-3 (administration & dosage), Female, Follow-Up Studies, France, Gestational Age, Humans, Incidence, Infant, Infant, Newborn, Male, Pregnancy, Pregnancy Complications (prevention & control), Pregnancy Outcome, Premature Birth (prevention & control), Prenatal Care (methods), Prenatal Nutritional Physiological Phenomena, Respiratory Distress Syndrome, Newborn (epidemiology), Respiratory Distress Syndrome, Newborn (prevention & control), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Fatty Acids, Omega-3.
- geographic : France.
- epidemiology : Respiratory Distress Syndrome, Newborn.
- methods : Prenatal Care.
- prevention & control : Pregnancy Complications, Premature Birth, Respiratory Distress Syndrome, Newborn.
- Adolescent, Adult, Dietary Supplements, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Gestational Age, Humans, Incidence, Infant, Infant, Newborn, Male, Pregnancy, Pregnancy Outcome, Prenatal Nutritional Physiological Phenomena, Treatment Outcome, Young Adult.
Abstract
Prenatal consumption of omega-3 fatty acids can act as an adjuvant in the development of the immune system and affect the inflammatory response of neonates.
We conducted a double-blind, randomized, placebo-controlled trial in Cuernavaca, Mexico. We randomly assigned 1,094 pregnant women (18-35 years of age) to receive 400 mg/d of algal docosahexaenoic acid (DHA) or placebo from 18 to 22 weeks of gestation through delivery. Birth outcomes and respiratory symptoms information until 18 months were available for 869 mother-child pairs. Questionnaires were administered, and maternal blood samples were obtained at baseline. Maternal atopy was based on specific IgE levels. During follow-up, information on infants’ respiratory symptoms was collected through questionnaires administered at 1, 3, 6, 9, 12, and 18 months of age. Negative binomial regression models were used to evaluate the effect of supplementation on respiratory symptoms in infants.
Among infants of atopic mothers, a statistically significant protective effect of DHA treatment was observed on phlegm with nasal discharge or nasal congestion (0.78; 95% CI, 0.60-1.02) and fever with phlegm and nasal discharge or nasal congestion (0.53; 95% CI, 0.29-0.99), adjusting for potential confounders.
Our results support the hypothesis that DHA supplementation during pregnancy may decrease the incidence of respiratory symptoms in children with a history of maternal atopy.
Url:
DOI: 10.1378/chest.13-1432
PubMed: 24626819
PubMed Central: 4122276
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001828
- to stream Pmc, to step Curation: 001688
- to stream Pmc, to step Checkpoint: 001428
- to stream PubMed, to step Corpus: 003594
- to stream PubMed, to step Curation: 003481
- to stream PubMed, to step Checkpoint: 003481
- to stream Ncbi, to step Merge: 001862
- to stream Ncbi, to step Curation: 001862
- to stream Ncbi, to step Checkpoint: 001862
- to stream Main, to step Merge: 003689
- to stream Main, to step Curation: 003666
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Omega-3 Fatty Acid Supplementation During Pregnancy and Respiratory Symptoms in Children</title><author><name sortKey="Escamilla Nu Ez, Maria Consuelo" sort="Escamilla Nu Ez, Maria Consuelo" uniqKey="Escamilla Nu Ez M" first="María Consuelo" last="Escamilla-Nu Ez">María Consuelo Escamilla-Nu Ez</name></author><author><name sortKey="Barraza Villarreal, Albino" sort="Barraza Villarreal, Albino" uniqKey="Barraza Villarreal A" first="Albino" last="Barraza-Villarreal">Albino Barraza-Villarreal</name></author><author><name sortKey="Hernandez Cadena, Leticia" sort="Hernandez Cadena, Leticia" uniqKey="Hernandez Cadena L" first="Leticia" last="Hernández-Cadena">Leticia Hernández-Cadena</name></author><author><name sortKey="Navarro Olivos, Efrain" sort="Navarro Olivos, Efrain" uniqKey="Navarro Olivos E" first="Efraín" last="Navarro-Olivos">Efraín Navarro-Olivos</name></author><author><name sortKey="Sly, Peter D" sort="Sly, Peter D" uniqKey="Sly P" first="Peter D." last="Sly">Peter D. Sly</name></author><author><name sortKey="Romieu, Isabelle" sort="Romieu, Isabelle" uniqKey="Romieu I" first="Isabelle" last="Romieu">Isabelle Romieu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24626819</idno><idno type="pmc">4122276</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122276</idno><idno type="RBID">PMC:4122276</idno><idno type="doi">10.1378/chest.13-1432</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001828</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001828</idno><idno type="wicri:Area/Pmc/Curation">001688</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001688</idno><idno type="wicri:Area/Pmc/Checkpoint">001428</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001428</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">003594</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003594</idno><idno type="wicri:Area/PubMed/Curation">003481</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003481</idno><idno type="wicri:Area/PubMed/Checkpoint">003481</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003481</idno><idno type="wicri:Area/Ncbi/Merge">001862</idno><idno type="wicri:Area/Ncbi/Curation">001862</idno><idno type="wicri:Area/Ncbi/Checkpoint">001862</idno><idno type="wicri:doubleKey">0012-3692:2014:Escamilla Nu Ez M:omega:fatty:acid</idno><idno type="wicri:Area/Main/Merge">003689</idno><idno type="wicri:Area/Main/Curation">003666</idno><idno type="wicri:Area/Main/Exploration">003666</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Omega-3 Fatty Acid Supplementation During Pregnancy and Respiratory Symptoms in Children</title><author><name sortKey="Escamilla Nu Ez, Maria Consuelo" sort="Escamilla Nu Ez, Maria Consuelo" uniqKey="Escamilla Nu Ez M" first="María Consuelo" last="Escamilla-Nu Ez">María Consuelo Escamilla-Nu Ez</name></author><author><name sortKey="Barraza Villarreal, Albino" sort="Barraza Villarreal, Albino" uniqKey="Barraza Villarreal A" first="Albino" last="Barraza-Villarreal">Albino Barraza-Villarreal</name></author><author><name sortKey="Hernandez Cadena, Leticia" sort="Hernandez Cadena, Leticia" uniqKey="Hernandez Cadena L" first="Leticia" last="Hernández-Cadena">Leticia Hernández-Cadena</name></author><author><name sortKey="Navarro Olivos, Efrain" sort="Navarro Olivos, Efrain" uniqKey="Navarro Olivos E" first="Efraín" last="Navarro-Olivos">Efraín Navarro-Olivos</name></author><author><name sortKey="Sly, Peter D" sort="Sly, Peter D" uniqKey="Sly P" first="Peter D." last="Sly">Peter D. Sly</name></author><author><name sortKey="Romieu, Isabelle" sort="Romieu, Isabelle" uniqKey="Romieu I" first="Isabelle" last="Romieu">Isabelle Romieu</name></author></analytic><series><title level="j">Chest</title><idno type="ISSN">0012-3692</idno><idno type="eISSN">1931-3543</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Dietary Supplements</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Fatty Acids, Omega-3 (administration & dosage)</term><term>Female</term><term>Follow-Up Studies</term><term>France</term><term>Gestational Age</term><term>Humans</term><term>Incidence</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Pregnancy</term><term>Pregnancy Complications (prevention & control)</term><term>Pregnancy Outcome</term><term>Premature Birth (prevention & control)</term><term>Prenatal Care (methods)</term><term>Prenatal Nutritional Physiological Phenomena</term><term>Respiratory Distress Syndrome, Newborn (epidemiology)</term><term>Respiratory Distress Syndrome, Newborn (prevention & control)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides gras omega-3 (administration et posologie)</term><term>Adolescent</term><term>Adulte</term><term>Complications de la grossesse ()</term><term>Compléments alimentaires</term><term>Femelle</term><term>France</term><term>Grossesse</term><term>Humains</term><term>Incidence</term><term>Issue de la grossesse</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Naissance prématurée ()</term><term>Nourrisson</term><term>Nouveau-né</term><term>Phénomènes physiologiques nutritionnels prénatals</term><term>Prise en charge prénatale ()</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Syndrome de détresse respiratoire du nouveau-né ()</term><term>Syndrome de détresse respiratoire du nouveau-né (épidémiologie)</term><term>Âge gestationnel</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Fatty Acids, Omega-3</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acides gras omega-3</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Respiratory Distress Syndrome, Newborn</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Prenatal Care</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pregnancy Complications</term><term>Premature Birth</term><term>Respiratory Distress Syndrome, Newborn</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Syndrome de détresse respiratoire du nouveau-né</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Dietary Supplements</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Gestational Age</term><term>Humans</term><term>Incidence</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Pregnancy</term><term>Pregnancy Outcome</term><term>Prenatal Nutritional Physiological Phenomena</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Complications de la grossesse</term><term>Compléments alimentaires</term><term>Femelle</term><term>France</term><term>Grossesse</term><term>Humains</term><term>Incidence</term><term>Issue de la grossesse</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Naissance prématurée</term><term>Nourrisson</term><term>Nouveau-né</term><term>Phénomènes physiologiques nutritionnels prénatals</term><term>Prise en charge prénatale</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Syndrome de détresse respiratoire du nouveau-né</term><term>Âge gestationnel</term><term>Études de suivi</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>BACKGROUND:</title><p>Prenatal consumption of omega-3 fatty acids can act as an adjuvant in the development of the immune system and affect the inflammatory response of neonates.</p></sec><sec><title>METHODS:</title><p>We conducted a double-blind, randomized, placebo-controlled trial in Cuernavaca, Mexico. We randomly assigned 1,094 pregnant women (18-35 years of age) to receive 400 mg/d of algal docosahexaenoic acid (DHA) or placebo from 18 to 22 weeks of gestation through delivery. Birth outcomes and respiratory symptoms information until 18 months were available for 869 mother-child pairs. Questionnaires were administered, and maternal blood samples were obtained at baseline. Maternal atopy was based on specific IgE levels. During follow-up, information on infants’ respiratory symptoms was collected through questionnaires administered at 1, 3, 6, 9, 12, and 18 months of age. Negative binomial regression models were used to evaluate the effect of supplementation on respiratory symptoms in infants.</p></sec><sec><title>RESULTS:</title><p>Among infants of atopic mothers, a statistically significant protective effect of DHA treatment was observed on phlegm with nasal discharge or nasal congestion (0.78; 95% CI, 0.60-1.02) and fever with phlegm and nasal discharge or nasal congestion (0.53; 95% CI, 0.29-0.99), adjusting for potential confounders.</p></sec><sec><title>CONCLUSIONS:</title><p>Our results support the hypothesis that DHA supplementation during pregnancy may decrease the incidence of respiratory symptoms in children with a history of maternal atopy.</p></sec><sec><title>TRIAL REGISTRY:</title><p><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">ClinicalTrials.gov</ext-link>; No.: NCT00646360; URL: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link></p></sec></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Barraza Villarreal, Albino" sort="Barraza Villarreal, Albino" uniqKey="Barraza Villarreal A" first="Albino" last="Barraza-Villarreal">Albino Barraza-Villarreal</name><name sortKey="Escamilla Nu Ez, Maria Consuelo" sort="Escamilla Nu Ez, Maria Consuelo" uniqKey="Escamilla Nu Ez M" first="María Consuelo" last="Escamilla-Nu Ez">María Consuelo Escamilla-Nu Ez</name><name sortKey="Hernandez Cadena, Leticia" sort="Hernandez Cadena, Leticia" uniqKey="Hernandez Cadena L" first="Leticia" last="Hernández-Cadena">Leticia Hernández-Cadena</name><name sortKey="Navarro Olivos, Efrain" sort="Navarro Olivos, Efrain" uniqKey="Navarro Olivos E" first="Efraín" last="Navarro-Olivos">Efraín Navarro-Olivos</name><name sortKey="Romieu, Isabelle" sort="Romieu, Isabelle" uniqKey="Romieu I" first="Isabelle" last="Romieu">Isabelle Romieu</name><name sortKey="Sly, Peter D" sort="Sly, Peter D" uniqKey="Sly P" first="Peter D." last="Sly">Peter D. Sly</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003666 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003666 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4122276
|texte= Omega-3 Fatty Acid Supplementation During Pregnancy and Respiratory Symptoms in Children
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24626819" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |